AMEDISYS INC (AMED)
US0234361089 - Common Stock
We assign a fundamental rating of 5 out of 10 to AMED. AMED was compared to 109 industry peers in the Health Care Providers & Services industry. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMED has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year AMED was profitable.
In the past year AMED had a positive cash flow from operations.
Of the past 5 years AMED 4 years were profitable.
AMED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 3.88%, AMED is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
AMED has a Return On Equity of 7.23%. This is in the better half of the industry: AMED outperforms 70.37% of its industry peers.
With an excellent Return On Invested Capital value of 9.98%, AMED belongs to the best of the industry, outperforming 87.04% of the companies in the same industry.
AMED had an Average Return On Invested Capital over the past 3 years of 11.18%. This is above the industry average of 8.15%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.88% | ||
| ROE | 7.23% | ||
| ROIC | 9.98% |
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%
1.3 Margins
With a decent Profit Margin value of 3.57%, AMED is doing good in the industry, outperforming 75.00% of the companies in the same industry.
AMED has a Operating Margin of 9.00%. This is amongst the best in the industry. AMED outperforms 81.48% of its industry peers.
In the last couple of years the Operating Margin of AMED has declined.
The Gross Margin of AMED (43.67%) is better than 72.22% of its industry peers.
AMED's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9% | ||
| PM (TTM) | 3.57% | ||
| GM | 43.67% |
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
The number of shares outstanding for AMED has been increased compared to 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
Compared to 1 year ago, AMED has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.67 indicates that AMED is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.67, AMED is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
AMED has a debt to FCF ratio of 1.88. This is a very positive value and a sign of high solvency as it would only need 1.88 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.88, AMED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
A Debt/Equity ratio of 0.30 indicates that AMED is not too dependend on debt financing.
The Debt to Equity ratio of AMED (0.30) is better than 63.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.88 | ||
| Altman-Z | 3.67 |
ROIC/WACC1.14
WACC8.74%
2.3 Liquidity
AMED has a Current Ratio of 1.19. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED's Current ratio of 1.19 is on the low side compared to the rest of the industry. AMED is outperformed by 65.74% of its industry peers.
A Quick Ratio of 1.19 indicates that AMED should not have too much problems paying its short term obligations.
The Quick ratio of AMED (1.19) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 |
3. Growth
3.1 Past
The earnings per share for AMED have decreased by -4.88% in the last year.
Measured over the past 5 years, AMED shows a small growth in Earnings Per Share. The EPS has been growing by 3.28% on average per year.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 4.19% in the last year.
AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.11% yearly.
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS Q2Q%2.04%
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Sales Q2Q%5.65%
3.2 Future
AMED is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.42% yearly.
AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.53% yearly.
EPS Next Y4.38%
EPS Next 2Y8.14%
EPS Next 3Y8.42%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y5.2%
Revenue Next 3Y6.53%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.69, which indicates a rather expensive current valuation of AMED.
AMED's Price/Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 70.37% of the companies in the same industry.
AMED's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.73.
The Price/Forward Earnings ratio is 16.84, which indicates a correct valuation of AMED.
Based on the Price/Forward Earnings ratio, AMED is valued a bit cheaper than 69.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of AMED to the average of the S&P500 Index (22.83), we can say AMED is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.69 | ||
| Fwd PE | 16.84 |
4.2 Price Multiples
AMED's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AMED is cheaper than 62.96% of the companies in the same industry.
83.33% of the companies in the same industry are more expensive than AMED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.59 | ||
| EV/EBITDA | 12.4 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)4.5
PEG (5Y)6
EPS Next 2Y8.14%
EPS Next 3Y8.42%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMEDISYS INC
NASDAQ:AMED (12/20/2024, 8:00:00 PM)
After market: 84.47 0 (0%)84.47
+0.69 (+0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners94.06%
Inst Owner Change-3.93%
Ins Owners2.08%
Ins Owner Change0.66%
Market Cap2.77B
Analysts53.75
Price Target99.32 (17.58%)
Short Float %8.1%
Short Ratio4.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.39%
Min EPS beat(2)-15.99%
Max EPS beat(2)9.21%
EPS beat(4)1
Avg EPS beat(4)-4.61%
Min EPS beat(4)-15.99%
Max EPS beat(4)9.21%
EPS beat(8)4
Avg EPS beat(8)2.21%
EPS beat(12)6
Avg EPS beat(12)2.76%
EPS beat(16)8
Avg EPS beat(16)2.98%
Revenue beat(2)1
Avg Revenue beat(2)-0.95%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)0.13%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-2.04%
Revenue beat(12)1
Avg Revenue beat(12)-2.8%
Revenue beat(16)1
Avg Revenue beat(16)-2.89%
PT rev (1m)-0.41%
PT rev (3m)-0.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.89%
EPS NY rev (1m)-4.67%
EPS NY rev (3m)-5.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)-0.21%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.69 | ||
| Fwd PE | 16.84 | ||
| P/S | 1.19 | ||
| P/FCF | 13.59 | ||
| P/OCF | 13.07 | ||
| P/B | 2.41 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.4 |
EPS(TTM)4.29
EY5.08%
EPS(NY)5.02
Fwd EY5.94%
FCF(TTM)6.21
FCFY7.36%
OCF(TTM)6.46
OCFY7.65%
SpS70.87
BVpS35.05
TBVpS-6
PEG (NY)4.5
PEG (5Y)6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.88% | ||
| ROE | 7.23% | ||
| ROCE | 12.64% | ||
| ROIC | 9.98% | ||
| ROICexc | 11.73% | ||
| ROICexgc | 260.89% | ||
| OM | 9% | ||
| PM (TTM) | 3.57% | ||
| GM | 43.67% | ||
| FCFM | 8.77% |
ROA(3y)5.6%
ROA(5y)7.71%
ROE(3y)10.94%
ROE(5y)15.06%
ROIC(3y)11.18%
ROIC(5y)12.42%
ROICexc(3y)11.68%
ROICexc(5y)13.03%
ROICexgc(3y)125.73%
ROICexgc(5y)225.54%
ROCE(3y)14.15%
ROCE(5y)15.72%
ROICexcg growth 3Y-41.4%
ROICexcg growth 5Y2.18%
ROICexc growth 3Y-10.39%
ROICexc growth 5Y-16.56%
OM growth 3Y-1.84%
OM growth 5Y-1.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.18%
GM growth 5Y1.92%
F-Score6
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.88 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 32.46% | ||
| Cap/Sales | 0.35% | ||
| Interest Coverage | 6.3 | ||
| Cash Conversion | 90.42% | ||
| Profit Quality | 245.38% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 1.19 | ||
| Altman-Z | 3.67 |
F-Score6
WACC8.74%
ROIC/WACC1.14
Cap/Depr(3y)34.64%
Cap/Depr(5y)33.05%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.88%
EPS 3Y-11.17%
EPS 5Y3.28%
EPS Q2Q%2.04%
EPS Next Y4.38%
EPS Next 2Y8.14%
EPS Next 3Y8.42%
EPS Next 5YN/A
Revenue 1Y (TTM)4.19%
Revenue growth 3Y2.59%
Revenue growth 5Y6.11%
Sales Q2Q%5.65%
Revenue Next Year5.05%
Revenue Next 2Y5.2%
Revenue Next 3Y6.53%
Revenue Next 5YN/A
EBIT growth 1Y19.66%
EBIT growth 3Y0.69%
EBIT growth 5Y4.48%
EBIT Next Year23.66%
EBIT Next 3Y12.97%
EBIT Next 5YN/A
FCF growth 1Y123.63%
FCF growth 3Y-24.01%
FCF growth 5Y-10.51%
OCF growth 1Y116.88%
OCF growth 3Y-21.99%
OCF growth 5Y-9.3%